A Look At ADMA Biologics (ADMA) Valuation After Analyst Downgrades And Channel Stuffing Allegations

Simply Wall St.04-21

ADMA Biologics (ADMA) is back in focus after recent analyst downgrades tied to allegations of Asceniv revenue channel stuffing, rising days' sales outstanding and accounts receivable, and criticism of...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629777705?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-21 10:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629777705","market":"nz","top_or_hot":-1,"title":"A Look At ADMA Biologics (ADMA) Valuation After Analyst Downgrades And Channel Stuffing Allegations","media":"Simply Wall St.","content":"<div>\n<p>ADMA Biologics (ADMA) is back in focus after recent analyst downgrades tied to allegations of Asceniv revenue channel stuffing, rising days' sales outstanding and accounts receivable, and criticism of...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/a-look-at-adma-biologics-adma-valuation-after-analyst-downgr\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At ADMA Biologics (ADMA) Valuation After Analyst Downgrades And Channel Stuffing Allegations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At ADMA Biologics (ADMA) Valuation After Analyst Downgrades And Channel Stuffing Allegations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-21 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/a-look-at-adma-biologics-adma-valuation-after-analyst-downgr><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ADMA Biologics (ADMA) is back in focus after recent analyst downgrades tied to allegations of Asceniv revenue channel stuffing, rising days' sales outstanding and accounts receivable, and criticism of...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/a-look-at-adma-biologics-adma-valuation-after-analyst-downgr\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADMA","symbol_name":"ADMA Biologics Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/a-look-at-adma-biologics-adma-valuation-after-analyst-downgr","article_id":"2629777705","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/a-look-at-adma-biologics-adma-valuation-after-analyst-downgr","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629777705","pubTimestamp":1776737413,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"ADMA Biologics (ADMA) is back in focus after recent analyst downgrades tied to allegations of Asceniv revenue channel stuffing, rising days' sales outstanding and accounts receivable, and criticism of the company’s public response.\nSee our latest analysis for ADMA Biologics.\nThe recent short report and analyst downgrades come after a difficult stretch for ADMA’s share price, with a 30 day share price return of a 24.02% decline and a year to date share price return of a 39.15% decline, even...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"ADMA":"ADMA Biologics Inc"},"translate_title":"分析师下调评级和渠道填充指控后ADMA Biologics(ADMA)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1.5},"content_text":"ADMA Biologics (ADMA) is back in focus after recent analyst downgrades tied to allegations of Asceniv revenue channel stuffing, rising days' sales outstanding and accounts receivable, and criticism of the company’s public response. See our latest analysis for ADMA Biologics. The recent short report and analyst downgrades come after a difficult stretch for ADMA’s share price, with a 30 day share price return of a 24.02% decline and a year to date share price return of a 39.15% decline, even though the 5 year total shareholder return is very large. If this kind of volatility has you comparing opportunities across the sector, it may be a good moment to scan a wider set of healthcare names through 35 healthcare AI stocks So with analyst concerns pulling ADMA’s share price sharply lower yet the stock still trading at a large discount to published price targets, are you looking at a potential mispricing here, or is the market already adjusting for future growth? AdvertisementMost Popular Narrative: 48% Undervalued According to the most followed valuation narrative, ADMA Biologics' fair value sits well above the recent $10.88 close, which is why the stock screens as materially undervalued in that framework. Reverse discounted cashflow at current TTM revenue of 383 MUSD at 35% FCF → 134 MUSD → revenue needs to grow 16%/y over next 10 years to justify current price (if ADMA gets to 1 BUSD of revenue by 2029 → growth of 21%/year) → currently undervalued Read the complete narrative. Curious what kind of revenue ramp, margins and future earnings multiple sit behind that fair value number? The narrative builds in ambitious but specific targets and a clear timeline. Result: Fair Value of $20.93 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on ADMA sustaining its current revenue and margin profile while managing scrutiny around ASCENIV sales practices and any potential impact on future product demand. Find out about the key risks to this ADMA Biologics narrative. Next Steps Given the mixed sentiment around valuation and short reports, it may be useful to act promptly and evaluate the thesis against the full picture of risks and rewards through 2 key rewards and 2 important warning signs Ready to hunt for more compelling ideas? If ADMA has sharpened your thinking on risk and reward, do not stop here. Broaden your watchlist now and give yourself more options tomorrow.  Target resilience first by checking companies in the solid balance sheet and fundamentals stocks screener (41 results) that can help anchor your portfolio when conditions get choppy. Seek value with discipline by scanning the 63 high quality undervalued stocks for businesses that pair quality fundamentals with prices that may leave room for upside. Add some punchy growth ideas by reviewing the 26 elite penny stocks with strong financials before the crowd starts paying closer attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629777705","isCrawlerRequest":true}